Adam Craig

Joe Stephenson1
Lyon Gleich1
John Nemunaitis1
1Joe Stephenson
1Lyon Gleich
Learn More
PURPOSE Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia. A subcutaneous (SC) formulation demonstrated efficacy and safety in phase 1/2 trials in patients previously treated with ≥1 tyrosine kinase inhibitor. This study assessed pharmacokinetics and safety of SC omacetaxine in patients(More)
  • 1